Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Rhabdoid Tumor | 12 | 2023 | 209 | 2.930 |
Why?
|
Brain Neoplasms | 38 | 2024 | 9065 | 1.660 |
Why?
|
Medulloblastoma | 8 | 2023 | 657 | 1.460 |
Why?
|
Central Nervous System Neoplasms | 13 | 2023 | 918 | 1.460 |
Why?
|
Cerebellar Neoplasms | 6 | 2023 | 571 | 1.270 |
Why?
|
Glioma | 23 | 2024 | 3491 | 1.270 |
Why?
|
Neoplasms, Germ Cell and Embryonal | 7 | 2022 | 483 | 1.180 |
Why?
|
Neuroectodermal Tumors, Primitive | 3 | 2022 | 135 | 1.140 |
Why?
|
Teratoma | 4 | 2023 | 402 | 0.630 |
Why?
|
Brain Stem Neoplasms | 6 | 2020 | 192 | 0.620 |
Why?
|
Ependymoma | 6 | 2021 | 310 | 0.610 |
Why?
|
Germinoma | 4 | 2022 | 124 | 0.610 |
Why?
|
Chromosomal Proteins, Non-Histone | 4 | 2022 | 723 | 0.540 |
Why?
|
Neuroblastoma | 4 | 2017 | 1263 | 0.480 |
Why?
|
Taxoids | 1 | 2018 | 665 | 0.470 |
Why?
|
Antineoplastic Agents, Phytogenic | 1 | 2018 | 615 | 0.450 |
Why?
|
Purines | 1 | 2017 | 616 | 0.430 |
Why?
|
Antineoplastic Combined Chemotherapy Protocols | 16 | 2023 | 11859 | 0.430 |
Why?
|
Neoplasm Recurrence, Local | 17 | 2023 | 9378 | 0.430 |
Why?
|
Child | 67 | 2024 | 80573 | 0.430 |
Why?
|
Cyclin-Dependent Kinase 4 | 1 | 2017 | 561 | 0.420 |
Why?
|
Aminopyridines | 1 | 2017 | 576 | 0.420 |
Why?
|
Child, Preschool | 43 | 2024 | 42511 | 0.400 |
Why?
|
Cyclin-Dependent Kinases | 1 | 2016 | 659 | 0.390 |
Why?
|
Pyrimidinones | 3 | 2020 | 384 | 0.310 |
Why?
|
Medical Oncology | 3 | 2019 | 2339 | 0.280 |
Why?
|
Myelitis, Transverse | 1 | 2006 | 39 | 0.270 |
Why?
|
Maximum Tolerated Dose | 3 | 2018 | 895 | 0.250 |
Why?
|
Pyridones | 3 | 2020 | 817 | 0.250 |
Why?
|
Adolescent | 42 | 2024 | 88819 | 0.250 |
Why?
|
Infant | 27 | 2024 | 36427 | 0.240 |
Why?
|
Neoplasms | 9 | 2024 | 22344 | 0.230 |
Why?
|
DNA-Binding Proteins | 4 | 2022 | 9601 | 0.230 |
Why?
|
Kidney Neoplasms | 3 | 2019 | 4282 | 0.230 |
Why?
|
National Cancer Institute (U.S.) | 2 | 2023 | 299 | 0.230 |
Why?
|
Fireflies | 1 | 2023 | 2 | 0.230 |
Why?
|
Combined Modality Therapy | 9 | 2023 | 8525 | 0.220 |
Why?
|
Pineal Gland | 2 | 2019 | 154 | 0.220 |
Why?
|
Radiotherapy | 3 | 2008 | 1491 | 0.220 |
Why?
|
Transplantation, Autologous | 4 | 2022 | 2125 | 0.210 |
Why?
|
Molecular Targeted Therapy | 6 | 2024 | 2824 | 0.210 |
Why?
|
Antineoplastic Agents | 6 | 2020 | 13635 | 0.200 |
Why?
|
Choriocarcinoma | 1 | 2022 | 121 | 0.200 |
Why?
|
Autopsy | 2 | 2019 | 1011 | 0.190 |
Why?
|
Disease-Free Survival | 9 | 2017 | 6840 | 0.190 |
Why?
|
Neurology | 1 | 2009 | 784 | 0.190 |
Why?
|
Sarcoma | 2 | 2022 | 1801 | 0.180 |
Why?
|
Humans | 83 | 2024 | 766117 | 0.180 |
Why?
|
Stem Cell Transplantation | 2 | 2006 | 1600 | 0.180 |
Why?
|
Astrocytoma | 2 | 2017 | 772 | 0.170 |
Why?
|
Neoplasms, Neuroepithelial | 1 | 2020 | 43 | 0.170 |
Why?
|
Glioblastoma | 3 | 2023 | 3458 | 0.170 |
Why?
|
Neoplasm Proteins | 2 | 2020 | 3594 | 0.160 |
Why?
|
Craniopharyngioma | 2 | 2012 | 276 | 0.160 |
Why?
|
Keratoderma, Palmoplantar | 1 | 2018 | 18 | 0.160 |
Why?
|
Mutation | 10 | 2024 | 30209 | 0.150 |
Why?
|
Carcinoma, Medullary | 1 | 2019 | 115 | 0.150 |
Why?
|
Prognosis | 16 | 2022 | 29912 | 0.150 |
Why?
|
DNA Helicases | 1 | 2023 | 852 | 0.150 |
Why?
|
Benzamides | 1 | 2023 | 1376 | 0.150 |
Why?
|
Osteosarcoma | 1 | 2004 | 908 | 0.150 |
Why?
|
Metabolic Clearance Rate | 1 | 2018 | 361 | 0.150 |
Why?
|
High-Throughput Nucleotide Sequencing | 4 | 2024 | 3665 | 0.150 |
Why?
|
Quinazolines | 2 | 2015 | 1366 | 0.140 |
Why?
|
Etoposide | 4 | 2023 | 636 | 0.140 |
Why?
|
Antigens, Neoplasm | 2 | 2002 | 1996 | 0.140 |
Why?
|
Neurofibromatosis 1 | 2 | 2020 | 561 | 0.140 |
Why?
|
Neurocytoma | 1 | 2016 | 28 | 0.130 |
Why?
|
Information Dissemination | 1 | 2024 | 1142 | 0.130 |
Why?
|
Drug Eruptions | 1 | 2019 | 334 | 0.130 |
Why?
|
Emigrants and Immigrants | 1 | 2022 | 550 | 0.130 |
Why?
|
Protein Kinase Inhibitors | 4 | 2023 | 5695 | 0.120 |
Why?
|
Young Adult | 17 | 2024 | 59868 | 0.120 |
Why?
|
Male | 40 | 2024 | 363935 | 0.120 |
Why?
|
Angiogenesis Inhibitors | 3 | 2013 | 2046 | 0.120 |
Why?
|
Proto-Oncogene Proteins B-raf | 3 | 2023 | 2054 | 0.120 |
Why?
|
Immunity, Cellular | 1 | 2020 | 1557 | 0.120 |
Why?
|
Pediatrics | 1 | 2009 | 3609 | 0.120 |
Why?
|
Hematologic Diseases | 1 | 2018 | 500 | 0.110 |
Why?
|
Survivors | 3 | 2024 | 2375 | 0.110 |
Why?
|
Transcription Factors | 3 | 2023 | 12130 | 0.110 |
Why?
|
Female | 40 | 2024 | 396233 | 0.110 |
Why?
|
Histones | 2 | 2022 | 2591 | 0.110 |
Why?
|
Salvage Therapy | 1 | 2020 | 1273 | 0.110 |
Why?
|
Child Mortality | 1 | 2015 | 204 | 0.110 |
Why?
|
Treatment Failure | 2 | 2018 | 2653 | 0.110 |
Why?
|
Oncolytic Virotherapy | 1 | 2019 | 520 | 0.110 |
Why?
|
Dose-Response Relationship, Drug | 4 | 2017 | 10737 | 0.110 |
Why?
|
Cancer Vaccines | 1 | 2020 | 1042 | 0.100 |
Why?
|
Diabetes Insipidus | 1 | 2013 | 143 | 0.100 |
Why?
|
Proteasome Endopeptidase Complex | 1 | 2019 | 1318 | 0.100 |
Why?
|
Choroid Plexus Neoplasms | 1 | 2012 | 38 | 0.100 |
Why?
|
Pituitary Diseases | 1 | 2013 | 137 | 0.100 |
Why?
|
Follow-Up Studies | 13 | 2020 | 39243 | 0.100 |
Why?
|
Retrospective Studies | 19 | 2024 | 81565 | 0.100 |
Why?
|
Repressor Proteins | 1 | 2002 | 2974 | 0.090 |
Why?
|
Kaplan-Meier Estimate | 3 | 2018 | 6506 | 0.090 |
Why?
|
Mutation, Missense | 1 | 2020 | 2590 | 0.090 |
Why?
|
Bone Neoplasms | 1 | 2004 | 2559 | 0.090 |
Why?
|
Genes, cdc | 1 | 2011 | 113 | 0.090 |
Why?
|
Infant Mortality | 1 | 2015 | 752 | 0.090 |
Why?
|
Hematopoietic Stem Cell Transplantation | 4 | 2016 | 5752 | 0.090 |
Why?
|
Skin Diseases | 1 | 2019 | 1083 | 0.090 |
Why?
|
Pituitary Gland | 1 | 2013 | 633 | 0.090 |
Why?
|
Flow Cytometry | 1 | 2020 | 5881 | 0.090 |
Why?
|
Recoverin | 1 | 2009 | 11 | 0.080 |
Why?
|
Neovascularization, Pathologic | 2 | 2013 | 2627 | 0.080 |
Why?
|
Intracranial Hypertension | 1 | 2012 | 190 | 0.080 |
Why?
|
Gastrointestinal Diseases | 1 | 2018 | 1204 | 0.080 |
Why?
|
Survival Rate | 8 | 2017 | 12827 | 0.080 |
Why?
|
Pons | 1 | 2010 | 239 | 0.080 |
Why?
|
Drug Hypersensitivity | 1 | 2018 | 903 | 0.080 |
Why?
|
Nuclear Proteins | 1 | 2023 | 5791 | 0.080 |
Why?
|
Matrix Metalloproteinase 14 | 1 | 2008 | 59 | 0.080 |
Why?
|
Genomics | 3 | 2024 | 5926 | 0.080 |
Why?
|
DNA Copy Number Variations | 1 | 2017 | 2045 | 0.080 |
Why?
|
Terminology as Topic | 1 | 2015 | 1536 | 0.080 |
Why?
|
Treatment Outcome | 11 | 2020 | 65219 | 0.070 |
Why?
|
Pinealoma | 1 | 2008 | 52 | 0.070 |
Why?
|
Infratentorial Neoplasms | 1 | 2008 | 94 | 0.070 |
Why?
|
Supratentorial Neoplasms | 1 | 2008 | 153 | 0.070 |
Why?
|
Medical Records | 1 | 2013 | 1408 | 0.070 |
Why?
|
Magnetic Resonance Imaging | 6 | 2020 | 36548 | 0.070 |
Why?
|
Adult | 19 | 2024 | 223139 | 0.070 |
Why?
|
Cyclophosphamide | 3 | 2013 | 2232 | 0.070 |
Why?
|
Early Diagnosis | 1 | 2012 | 1186 | 0.070 |
Why?
|
DNA, Neoplasm | 2 | 2010 | 1739 | 0.070 |
Why?
|
CD8-Positive T-Lymphocytes | 1 | 2020 | 4649 | 0.070 |
Why?
|
Meningeal Neoplasms | 1 | 2016 | 1252 | 0.070 |
Why?
|
Matrix Metalloproteinase 2 | 1 | 2008 | 462 | 0.070 |
Why?
|
Interdisciplinary Communication | 1 | 2012 | 931 | 0.070 |
Why?
|
Cell Cycle Proteins | 2 | 2022 | 3436 | 0.060 |
Why?
|
Thalidomide | 2 | 2013 | 886 | 0.060 |
Why?
|
Vincristine | 2 | 2007 | 1037 | 0.060 |
Why?
|
Mesna | 1 | 2004 | 62 | 0.060 |
Why?
|
Drug Resistance, Neoplasm | 1 | 2020 | 5336 | 0.060 |
Why?
|
Cerebral Arteries | 1 | 2007 | 490 | 0.060 |
Why?
|
Intelligence | 1 | 2009 | 922 | 0.060 |
Why?
|
Receptor Protein-Tyrosine Kinases | 1 | 2011 | 1621 | 0.060 |
Why?
|
Moyamoya Disease | 1 | 2007 | 273 | 0.050 |
Why?
|
Immunotherapy | 1 | 2019 | 4746 | 0.050 |
Why?
|
Gene Dosage | 3 | 2017 | 1213 | 0.050 |
Why?
|
Leucovorin | 1 | 2004 | 643 | 0.050 |
Why?
|
Cisplatin | 2 | 2007 | 1654 | 0.050 |
Why?
|
Epigenesis, Genetic | 1 | 2016 | 3818 | 0.050 |
Why?
|
United States | 3 | 2023 | 72920 | 0.050 |
Why?
|
Off-Label Use | 1 | 2024 | 185 | 0.050 |
Why?
|
Receptor, erbB-2 | 1 | 2013 | 2593 | 0.050 |
Why?
|
Administration, Oral | 3 | 2018 | 4016 | 0.050 |
Why?
|
In Situ Hybridization, Fluorescence | 3 | 2019 | 2510 | 0.050 |
Why?
|
Methotrexate | 2 | 2007 | 1719 | 0.050 |
Why?
|
Central Nervous System | 2 | 2022 | 1343 | 0.050 |
Why?
|
TOR Serine-Threonine Kinases | 2 | 2020 | 2057 | 0.050 |
Why?
|
Bone Marrow | 2 | 2002 | 2916 | 0.050 |
Why?
|
Remission Induction | 2 | 2005 | 2413 | 0.050 |
Why?
|
Patient Care Team | 1 | 2012 | 2517 | 0.040 |
Why?
|
Camptothecin | 2 | 2017 | 598 | 0.040 |
Why?
|
Proto-Oncogene Proteins c-mdm2 | 1 | 2022 | 361 | 0.040 |
Why?
|
Ribonuclease III | 1 | 2022 | 271 | 0.040 |
Why?
|
Feasibility Studies | 4 | 2018 | 5300 | 0.040 |
Why?
|
Mitogen-Activated Protein Kinase Kinases | 1 | 2022 | 634 | 0.040 |
Why?
|
Radiation Injuries | 1 | 2007 | 1181 | 0.040 |
Why?
|
Infant, Newborn | 4 | 2024 | 26381 | 0.040 |
Why?
|
Lung Neoplasms | 1 | 2004 | 13483 | 0.040 |
Why?
|
Neoplasm Staging | 3 | 2017 | 11200 | 0.040 |
Why?
|
Disease Progression | 3 | 2024 | 13616 | 0.040 |
Why?
|
DEAD-box RNA Helicases | 1 | 2022 | 386 | 0.040 |
Why?
|
Contrast Media | 1 | 2012 | 5330 | 0.040 |
Why?
|
Chemotherapy, Adjuvant | 2 | 2005 | 3546 | 0.040 |
Why?
|
Thymidine Kinase | 1 | 2019 | 286 | 0.040 |
Why?
|
Basal Ganglia | 1 | 2021 | 550 | 0.040 |
Why?
|
Clinical Trials as Topic | 3 | 2024 | 8038 | 0.040 |
Why?
|
Japan | 1 | 2022 | 1414 | 0.040 |
Why?
|
Microsatellite Repeats | 1 | 2020 | 784 | 0.040 |
Why?
|
Consensus | 2 | 2019 | 3202 | 0.040 |
Why?
|
Sequence Analysis, DNA | 2 | 2020 | 4780 | 0.040 |
Why?
|
Oximes | 1 | 2019 | 305 | 0.040 |
Why?
|
DNA Mismatch Repair | 1 | 2020 | 432 | 0.030 |
Why?
|
Prodrugs | 1 | 2019 | 274 | 0.030 |
Why?
|
Diagnosis, Differential | 1 | 2012 | 12976 | 0.030 |
Why?
|
Cognition | 2 | 2016 | 7050 | 0.030 |
Why?
|
Prospective Studies | 5 | 2018 | 54812 | 0.030 |
Why?
|
Antineoplastic Agents, Alkylating | 1 | 2020 | 614 | 0.030 |
Why?
|
Amino Acid Substitution | 1 | 2020 | 1742 | 0.030 |
Why?
|
Mutagenesis | 1 | 2020 | 1227 | 0.030 |
Why?
|
Comparative Genomic Hybridization | 1 | 2017 | 474 | 0.030 |
Why?
|
Doxorubicin | 1 | 2022 | 2226 | 0.030 |
Why?
|
Proto-Oncogene Proteins c-raf | 1 | 2016 | 205 | 0.030 |
Why?
|
Reverse Transcriptase Polymerase Chain Reaction | 1 | 2002 | 4565 | 0.030 |
Why?
|
Neoplasm Transplantation | 1 | 2019 | 2010 | 0.030 |
Why?
|
Thalamus | 1 | 2021 | 1040 | 0.030 |
Why?
|
Adenoviridae | 1 | 2019 | 1092 | 0.030 |
Why?
|
Biological Availability | 1 | 2015 | 387 | 0.030 |
Why?
|
Epigenomics | 1 | 2020 | 959 | 0.030 |
Why?
|
Animals | 6 | 2023 | 168800 | 0.030 |
Why?
|
Radiotherapy Dosage | 1 | 2021 | 2863 | 0.030 |
Why?
|
Genetic Predisposition to Disease | 1 | 2016 | 18076 | 0.030 |
Why?
|
Ubiquitin | 1 | 2019 | 840 | 0.030 |
Why?
|
Survival Analysis | 3 | 2017 | 10087 | 0.030 |
Why?
|
Neoplastic Stem Cells | 1 | 2001 | 1351 | 0.030 |
Why?
|
Sirolimus | 1 | 2020 | 1541 | 0.030 |
Why?
|
Fenofibrate | 1 | 2013 | 87 | 0.030 |
Why?
|
Biopsy | 2 | 2018 | 6768 | 0.030 |
Why?
|
Incidence | 3 | 2022 | 21513 | 0.030 |
Why?
|
Morbidity | 1 | 2018 | 1753 | 0.030 |
Why?
|
Gene Frequency | 1 | 2020 | 3623 | 0.030 |
Why?
|
Imidazoles | 1 | 2019 | 1169 | 0.030 |
Why?
|
Mice, Nude | 1 | 2019 | 3610 | 0.030 |
Why?
|
Signal Transduction | 2 | 2013 | 23605 | 0.030 |
Why?
|
Neoadjuvant Therapy | 1 | 2004 | 2897 | 0.020 |
Why?
|
Mice | 4 | 2023 | 81839 | 0.020 |
Why?
|
Sensitivity and Specificity | 2 | 2009 | 14645 | 0.020 |
Why?
|
Hearing | 1 | 2016 | 505 | 0.020 |
Why?
|
Quality of Life | 2 | 2024 | 13468 | 0.020 |
Why?
|
SEER Program | 1 | 2017 | 1443 | 0.020 |
Why?
|
Tumor Suppressor Protein p53 | 1 | 2022 | 2946 | 0.020 |
Why?
|
Viral Proteins | 1 | 2019 | 1801 | 0.020 |
Why?
|
Xenograft Model Antitumor Assays | 1 | 2020 | 3604 | 0.020 |
Why?
|
Alleles | 2 | 2019 | 6892 | 0.020 |
Why?
|
Kidney | 2 | 2019 | 7072 | 0.020 |
Why?
|
Recurrence | 1 | 2023 | 8494 | 0.020 |
Why?
|
Sequence Analysis, RNA | 1 | 2019 | 2039 | 0.020 |
Why?
|
Zebrafish | 1 | 2022 | 3035 | 0.020 |
Why?
|
Time Factors | 4 | 2015 | 40108 | 0.020 |
Why?
|
Cell Cycle | 1 | 2019 | 2920 | 0.020 |
Why?
|
Neuropsychological Tests | 2 | 2017 | 7119 | 0.020 |
Why?
|
RNA Interference | 1 | 2019 | 2828 | 0.020 |
Why?
|
Pilot Projects | 1 | 2023 | 8724 | 0.020 |
Why?
|
Proto-Oncogene Proteins | 1 | 2022 | 4521 | 0.020 |
Why?
|
alpha-Fetoproteins | 1 | 2010 | 227 | 0.020 |
Why?
|
Gene Expression | 1 | 2002 | 7582 | 0.020 |
Why?
|
Cell Line, Tumor | 2 | 2019 | 17071 | 0.020 |
Why?
|
Risk Factors | 4 | 2015 | 74857 | 0.020 |
Why?
|
Postoperative Period | 1 | 2014 | 1820 | 0.020 |
Why?
|
Genetic Vectors | 1 | 2019 | 3400 | 0.020 |
Why?
|
Statistics as Topic | 1 | 2015 | 2351 | 0.020 |
Why?
|
Tomography, X-Ray Computed | 1 | 2012 | 20700 | 0.020 |
Why?
|
Gene Expression Profiling | 2 | 2017 | 9527 | 0.020 |
Why?
|
Boston | 2 | 2014 | 9335 | 0.020 |
Why?
|
Genes, Tumor Suppressor | 1 | 2012 | 1060 | 0.020 |
Why?
|
Organ Size | 1 | 2013 | 2260 | 0.020 |
Why?
|
Retinoblastoma Protein | 1 | 2011 | 666 | 0.020 |
Why?
|
Spinal Cord | 1 | 2016 | 1811 | 0.020 |
Why?
|
Thiotepa | 1 | 2007 | 66 | 0.020 |
Why?
|
Vascular Endothelial Growth Factor Receptor-2 | 1 | 2010 | 548 | 0.020 |
Why?
|
Circle of Willis | 1 | 2007 | 76 | 0.020 |
Why?
|
Genome, Human | 1 | 2020 | 4443 | 0.020 |
Why?
|
Optic Chiasm | 1 | 2007 | 89 | 0.020 |
Why?
|
Gene Amplification | 1 | 2011 | 1088 | 0.020 |
Why?
|
Oncogenes | 1 | 2012 | 1232 | 0.020 |
Why?
|
Antiviral Agents | 1 | 2019 | 3068 | 0.020 |
Why?
|
Registries | 1 | 2022 | 8347 | 0.020 |
Why?
|
Delivery of Health Care | 1 | 2024 | 5367 | 0.020 |
Why?
|
Chronic Disease | 1 | 2021 | 9354 | 0.020 |
Why?
|
Specimen Handling | 1 | 2010 | 704 | 0.020 |
Why?
|
Soft Tissue Neoplasms | 1 | 2014 | 1163 | 0.020 |
Why?
|
Age Factors | 2 | 2015 | 18386 | 0.020 |
Why?
|
Endostatins | 1 | 2005 | 167 | 0.020 |
Why?
|
Mass Spectrometry | 1 | 2012 | 2195 | 0.020 |
Why?
|
Dose-Response Relationship, Radiation | 1 | 2007 | 870 | 0.020 |
Why?
|
Polysomnography | 1 | 2012 | 1868 | 0.020 |
Why?
|
Polymorphism, Single Nucleotide | 2 | 2017 | 16040 | 0.020 |
Why?
|
Cause of Death | 1 | 2015 | 3715 | 0.010 |
Why?
|
Thrombospondins | 1 | 2005 | 197 | 0.010 |
Why?
|
Drug Therapy | 1 | 2008 | 504 | 0.010 |
Why?
|
Tumor Suppressor Proteins | 1 | 2014 | 2795 | 0.010 |
Why?
|
Carboplatin | 1 | 2007 | 787 | 0.010 |
Why?
|
Biomedical Research | 1 | 2019 | 3458 | 0.010 |
Why?
|
Gene Expression Regulation, Neoplastic | 1 | 2020 | 8612 | 0.010 |
Why?
|
Sulfonamides | 1 | 2013 | 1980 | 0.010 |
Why?
|
Genetic Testing | 1 | 2017 | 3594 | 0.010 |
Why?
|
Fibroblast Growth Factor 2 | 1 | 2005 | 590 | 0.010 |
Why?
|
Pyrazoles | 1 | 2013 | 2031 | 0.010 |
Why?
|
Cell Survival | 1 | 2013 | 5747 | 0.010 |
Why?
|
Cytoskeletal Proteins | 1 | 2008 | 1322 | 0.010 |
Why?
|
Radiography | 1 | 2013 | 6943 | 0.010 |
Why?
|
Phenotype | 1 | 2020 | 16716 | 0.010 |
Why?
|
Proto-Oncogene Proteins c-bcl-2 | 1 | 2008 | 1407 | 0.010 |
Why?
|
Immunohistochemistry | 2 | 2008 | 11035 | 0.010 |
Why?
|
Secondary Prevention | 1 | 2008 | 1470 | 0.010 |
Why?
|
Ploidies | 1 | 2001 | 287 | 0.010 |
Why?
|
S100 Proteins | 1 | 2001 | 214 | 0.010 |
Why?
|
Gangliosides | 1 | 2001 | 132 | 0.010 |
Why?
|
Cell Movement | 1 | 2013 | 5196 | 0.010 |
Why?
|
Schwann Cells | 1 | 2001 | 195 | 0.010 |
Why?
|
Genes, myc | 1 | 2001 | 391 | 0.010 |
Why?
|
Radiotherapy, Adjuvant | 1 | 2005 | 1777 | 0.010 |
Why?
|
Phosphorylation | 1 | 2010 | 8292 | 0.010 |
Why?
|
Positron-Emission Tomography | 1 | 2015 | 6545 | 0.010 |
Why?
|
Diffusion Magnetic Resonance Imaging | 1 | 2010 | 2805 | 0.010 |
Why?
|
Cross-Sectional Studies | 1 | 2019 | 26290 | 0.010 |
Why?
|
Cells, Cultured | 1 | 2013 | 18967 | 0.010 |
Why?
|
Neurosurgical Procedures | 1 | 2008 | 2078 | 0.010 |
Why?
|
Predictive Value of Tests | 1 | 2013 | 15403 | 0.010 |
Why?
|
Stromal Cells | 1 | 2001 | 1332 | 0.010 |
Why?
|
Neoplasm, Residual | 1 | 2000 | 1009 | 0.010 |
Why?
|
Vascular Endothelial Growth Factor A | 1 | 2005 | 3501 | 0.010 |
Why?
|
Risk Assessment | 1 | 2015 | 24276 | 0.010 |
Why?
|
Antibodies, Monoclonal | 1 | 2010 | 9237 | 0.010 |
Why?
|
Cohort Studies | 1 | 2016 | 41684 | 0.010 |
Why?
|
Comorbidity | 1 | 2007 | 10579 | 0.010 |
Why?
|
Genome-Wide Association Study | 1 | 2011 | 12803 | 0.010 |
Why?
|
Obesity | 1 | 2012 | 13085 | 0.010 |
Why?
|